Research programme: AMP-activated protein kinase stimulants - Energenesis Biomedical
Alternative Names: ENERGI F704; ENERGI F705; ENERGI F706; ENERGI F707; ENERGI-F702; F701; F702; F703; F704; F705; F707; F708; F711Latest Information Update: 31 Aug 2023
At a glance
- Originator Energenesis Biomedical
- Class Anti-inflammatories; Antineoplastics; Skin disorder therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic foot ulcer; Inflammation; Metabolic disorders; Mitochondrial disorders; Neurodegenerative disorders; Skin disorders
- No development reported Cancer
Most Recent Events
- 31 Aug 2023 Preclinical trials is ongoing in Inflammation in Taiwan (unspecified route) (Energenesis biomedical pipeline, August 2023)
- 31 Aug 2023 Preclinical trials is ongoing in Metabolic disorders in Taiwan (unspecified route) (Energenesis biomedical pipeline, August 2023)
- 31 Aug 2023 Preclinical trials is ongoing in Neurodegenerative disorders in Taiwan (unspecified route) (Energenesis biomedical pipeline, August 2023)